“HER2-Low” and the Challenge of Repurposing Legacy HER2 IHC Biomarker Assays

In September 2022, the US Food and Drug Administration (FDA) expanded approval of the legacy Roche monoclonal antibody 4B5-based immunohistochemistry (IHC) assay to identify patients with HER2-low breast cancers predicted to respond to trastuzumab deruxtecan (T-DXd), based on findings from the DESTI...

Полное описание

Библиографические подробности

Главные авторы:	Emina E. Torlakovic, Allen M. Gown
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2026-03-01
Серии:	Current Oncology
Предметы:	HER2-low biomarker repurposing immunohistochemistry trastuzumab deruxtecan companion diagnostic assay validation
Online-ссылка:	https://www.mdpi.com/1718-7729/33/4/181
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!